CNAT Conatus Pharmaceuticals Inc.

1.52
0  0%
Previous Close 1.52
Open 1.52
Price To Book 3.04
Market Cap 50378980
Shares 33,144,066
Volume 878,143
Short Ratio
Av. Daily Volume 829,927

SEC filingsSee all SEC filings

  1. 8-K - Current report 181218888
  2. 8-K - Current report 181218887
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181154859
  4. 8-K - Current report 181153705
  5. 8-K - Current report 181069022

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due mid-2019.
Emricasan
NASH cirrhosis - ENCORE-LF trial
Phase 2b data released December 5, 2018 did not meet primary endpoint.
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 topline data released Jan 2015
Emricasan
Acute-on-Chronic Liver Failure (ACLF)
Phase 2b data released April 4, 2018. Primary endpoint not met.
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2 data are due 1H 2019.
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 topline data released early January 2016
Emricasan
Liver Cirrhosis
Phase 2 data released September 2015.
Emricasan
Portal Hypertension

Latest News

  1. The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
  2. Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
  3. The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
  4. Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
  5. Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint
  6. Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis
  7. Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
  8. When Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Become Profitable?
  9. Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals — Discovering Underlying Factors of Influence
  10. Do Options Traders Know Something About Conatus (CNAT) Stock We Don't?
  11. Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT
  12. Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting
  13. Today’s Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals
  14. Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates
  15. Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates
  16. Conatus: 3Q Earnings Snapshot
  17. Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates
  18. Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results
  19. Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock

SEC Filings

  1. 8-K - Current report 181218888
  2. 8-K - Current report 181218887
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181154859
  4. 8-K - Current report 181153705
  5. 8-K - Current report 181069022
  6. 424B5 - Prospectus [Rule 424(b)(5)] 18988568
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988327
  8. 8-K - Current report 18984758
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18945942
  10. 8-K - Current report 18917102